Abstract

BackgroundDenosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by inhibiting RANKL, a key mediator of osteoclast formation, function, and survival.ObjectivesTo evaluate the effect of denosumab...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call